March 13, 2018 / 11:11 AM / 5 months ago

BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis

March 13 (Reuters) - Protalix Biotherapeutics Inc:

* PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 FOR THE TREATMENT OF ULCERATIVE COLITIS

* PROTALIX BIOTHERAPEUTICS INC - KEY EFFICACY ENDPOINTS OF STUDY WERE MET

* PROTALIX BIOTHERAPEUTICS INC - OPRX-106 WAS SAFE AND WELL TOLERATED WITH ONLY MILD TO MODERATE ADVERSE EVENTS IN STUDY

* PROTALIX BIOTHERAPEUTICS INC - NO ANTI-DRUG ANTIBODIES WERE DETECTED IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below